Evidence map›Paper›PMID 35053473›Full record

ArticleCancers2022

Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy.

Kun-Han Lue, Chun-Hou Huang, Tsung-Cheng Hsieh, Shu-Hsin Liu, Yi-Feng Wu, Yu-Hung Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. The prognostic value ofAnnals of nuclear medicine · 2026
    Article
  2. Article
  3. Prognostic Value ofKorean journal of radiology · 2024
    Article
  4. Article
  5. Article
  6. The value ofTzu chi medical journal
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kun-Han LueDepartment of Medical Imaging and Radiological Sciences, Tzu Chi University of Science and Technology, Hualien 970302, Taiwan.
Chun-Hou HuangDepartment of Nursing, Tzu Chi University, Hualien 970374, Taiwan.
Tsung-Cheng HsiehInstitute of Medical Sciences, Tzu Chi University, Hualien 970374, Taiwan.
Shu-Hsin LiuDepartment of Medical Imaging and Radiological Sciences, Tzu Chi University of Science and Technology, Hualien 970302, Taiwan.
Yi-Feng WuSchool of Medicine, College of Medicine, Tzu Chi University, Hualien 970374, Taiwan.
Yu-Hung ChenDepartment of Nuclear Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970473, Taiwan.ORCID 0000-0002-9227-0731
Tzu Chi University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors (TKIs) are the first-line treatment for patients with advanced epidermal growth factor receptor (

Indexed as

epidermal growth factor receptor (EGFR)lung adenocarcinomaprognostic biomarkersystemic inflammation index (SII)tumor heterogeneitytyrosine kinase inhibitor (TKI)

Identifiers

PMID35053473
PMCPMC8773680
OpenAlexW4205327554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.